{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:56:58Z","timestamp":1790312218191,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke\/National Institute of Health","doi-asserted-by":"publisher","award":["NS047198"],"award-info":[{"award-number":["NS047198"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wayne State President Research Enhancement"},{"DOI":"10.13039\/100000065","name":"NIH\/NINDS","doi-asserted-by":"publisher","award":["NS086778"],"award-info":[{"award-number":["NS086778"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.05.019","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:01:06Z","timestamp":1495238466000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses \u03b1-syn- and MPTP-induced toxicities in\u00a0vivo"],"prefix":"10.1016","volume":"123","author":[{"given":"Banibrata","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnanada S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokol V.","family":"Todi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-0538","authenticated-orcid":false,"given":"Aloke K.","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.05.019_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","article-title":"Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex","volume":"108","author":"Beal","year":"1992","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J.\u00a0Neurochem."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.05.019_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jnc.13425","article-title":"Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics","volume":"139","author":"Belaidi","year":"2016","journal-title":"J.\u00a0Neurochem."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2017.05.019_bib4","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1002\/mds.22540","article-title":"Transcranial ultrasound as a risk marker for Parkinson's disease","volume":"24","author":"Berg","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2007.06.052","article-title":"Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study","volume":"424","author":"Bharathi","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10072-012-1156-0","article-title":"Rifampicin and Parkinson's disease","volume":"34","author":"Bi","year":"2013","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib7","first-page":"851","article-title":"The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961","volume":"113","author":"Birkmayer","year":"2001","journal-title":"Wien. Klin. Wochenschr."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib8","doi-asserted-by":"crossref","first-page":"e36542","DOI":"10.1371\/journal.pone.0036542","article-title":"Ubiquitin-specific protease 25 functions in Endoplasmic Reticulum-associated degradation","volume":"7","author":"Blount","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib9","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1038\/ncomms5638","article-title":"Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23","volume":"5","author":"Blount","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0304-3940(00)00948-4","article-title":"Extracellular toxicity of 6-hydroxydopamine on PC12 cells","volume":"283","author":"Blum","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev.neuro.26.041002.131425","article-title":"Human neurodegenerative disease modeling using Drosophila","volume":"26","author":"Bonini","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib12","doi-asserted-by":"crossref","first-page":"24209","DOI":"10.1074\/jbc.270.41.24209","article-title":"Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II)","volume":"270","author":"Breuer","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/jnr.23395","article-title":"Using membrane-targeted green fluorescent protein to monitor neurotoxic protein-dependent degeneration of Drosophila eyes","volume":"92","author":"Burr","year":"2014","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/abio.1996.0032","article-title":"A\u00a0fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells","volume":"233","author":"Cabantchik","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.yexcr.2005.02.018","article-title":"Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation\u2013implications for prolyl hydroxylase activity and iron","volume":"306","author":"Callapina","year":"2005","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/156720508786898523","article-title":"Metal catalyzed oxidation of alpha-synuclein\u2013a role for oligomerization in pathology?","volume":"5","author":"Cole","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism\u2013chronic treatment with L-dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","article-title":"Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology","volume":"111","author":"Danzer","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/acschemneuro.6b00356","article-title":"A\u00a0novel iron(II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson's disease","volume":"8","author":"Das","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib20","doi-asserted-by":"crossref","first-page":"9179","DOI":"10.1021\/acs.jmedchem.5b01031","volume":"58","author":"Das","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1087753","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib23","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1038\/399a032","article-title":"Prospects for new restorative and neuroprotective treatments in Parkinson's disease","volume":"399","author":"Dunnett","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib24","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.bmc.2004.06.019","article-title":"Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthale n-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors","volume":"12","author":"Dutta","year":"2004","journal-title":"Bioorg Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/35006074","article-title":"A\u00a0Drosophila model of Parkinson's disease","volume":"404","author":"Feany","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","article-title":"Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice","volume":"7","author":"Finkelstein","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.neuropharm.2017.05.019_bib27","first-page":"133","article-title":"Potential sources of increased iron in the substantia nigra of parkinsonian patients","author":"Gerlach","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib28","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm901618d","volume":"53","author":"Ghosh","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib29","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.45.6.1138","article-title":"Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease","volume":"45","author":"Gorell","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12883-015-0331-3","article-title":"Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease","volume":"15","author":"Grolez","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2016.03.016","article-title":"Deferoxamine-mediated up-regulation of HIF-1alpha prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice","volume":"280","author":"Guo","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib32","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1021\/jm00076a014","article-title":"Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives","volume":"36","author":"Hales","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib33","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.192342099","article-title":"Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor","volume":"99","author":"Ivan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genet-110711-155456","article-title":"Probing mechanisms that underlie human neurodegenerative diseases in Drosophila","volume":"46","author":"Jaiswal","year":"2012","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0014-4886(03)00353-4","article-title":"Neuroprotective effects of the novel D3\/D2 receptor agonist and antiparkinson agent, S32504, in\u00a0vitro against 1-methyl-4-phenylpyridinium (MPP+) and in\u00a0vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole","volume":"184","author":"Joyce","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib36","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","article-title":"Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in\u00a0vivo: a novel therapy for Parkinson's disease","volume":"37","author":"Kaur","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib38","doi-asserted-by":"crossref","first-page":"29065","DOI":"10.1074\/jbc.M109.000638","article-title":"Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease","volume":"284","author":"Lee","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.nbd.2015.03.015","article-title":"Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse","volume":"81","author":"Lei","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib40","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/jnr.22405","article-title":"Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin","volume":"88","author":"Li","year":"2010","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib41","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00702-010-0518-0","article-title":"Iron chelation and neuroprotection in neurodegenerative diseases","volume":"118","author":"Li","year":"2011","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(76)91416-1","article-title":"\u201cOn-off\u201d effects in patients with Parkinson's disease on chronic levodopa therapy","volume":"1","author":"Marsden","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/cn500084x","article-title":"Multifunctional D2\/D3 agonist D-520 with high in\u00a0vivo efficacy: modulator of toxicity of alpha-synuclein aggregates","volume":"5","author":"Modi","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib45","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/01.wnl.0000262033.01945.9a","article-title":"Individual dopaminergic neurons show raised iron levels in Parkinson disease","volume":"68","author":"Oakley","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib46","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"22","author":"Olanow","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib48","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","article-title":"The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity","volume":"20","author":"Ostrerova-Golts","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1369\/jhc.2008.950246","article-title":"A\u00a0rapid method combining Golgi and Nissl staining to study neuronal morphology and cytoarchitecture","volume":"56","author":"Pilati","year":"2008","journal-title":"J.\u00a0Histochem Cytochem"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib50","first-page":"135","article-title":"The parkinsonian toxin MPTP: action and mechanism","volume":"16","author":"Przedborski","year":"2000","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1023\/B:JOBB.0000041771.66775.d5","article-title":"MPTP as a mitochondrial neurotoxic model of Parkinson's disease","volume":"36","author":"Przedborski","year":"2004","journal-title":"J.\u00a0Bioenerg. Biomembr."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib52","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1523\/JNEUROSCI.3117-15.2016","article-title":"Regulation of ATP13A2 via PHD2-HIF1alpha signaling is critical for cellular iron homeostasis: implications for Parkinson's disease","volume":"36","author":"Rajagopalan","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib53","doi-asserted-by":"crossref","first-page":"24301","DOI":"10.1074\/jbc.M010806200","article-title":"Intracellular chelation of iron by bipyridyl inhibits DNA virus replication: ribonucleotide reductase maturation as a probe of intracellular iron pools","volume":"276","author":"Romeo","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.spen.2006.08.002","article-title":"Brain iron metabolism","volume":"13","author":"Rouault","year":"2006","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib55","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/cn400106n","article-title":"D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in\u00a0vivo efficacy in a Parkinson's disease animal model","volume":"4","author":"Santra","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrd1803","article-title":"Rasagiline","volume":"4","author":"Schapira","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions","volume":"291","author":"Schapira","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/jnc.12767","article-title":"The high-affinity D2\/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease","volume":"131","author":"Shah","year":"2014","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib59","doi-asserted-by":"crossref","first-page":"41732","DOI":"10.1074\/jbc.M504963200","article-title":"Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system","volume":"280","author":"Siddiq","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib60","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1073\/pnas.88.9.3671","article-title":"Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1","volume":"88","author":"Smiley","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib61","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","article-title":"Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease","volume":"74","author":"Soto-Otero","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.05.019_bib63","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1038\/ncomms6181","article-title":"A\u00a0viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson's disease","volume":"5","author":"Szelechowski","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib64","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1093\/hmg\/ddv174","article-title":"DnaJ-1 and karyopherin alpha3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6","volume":"24","author":"Tsou","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2015.05.010","article-title":"The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster","volume":"82","author":"Tsou","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib66","doi-asserted-by":"crossref","first-page":"44284","DOI":"10.1074\/jbc.M105343200","article-title":"Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure","volume":"276","author":"Uversky","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nbt1387","article-title":"Large-scale chemical dissection of mitochondrial function","volume":"26","author":"Wagner","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","article-title":"Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators","volume":"62","author":"Weinreb","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib69","doi-asserted-by":"crossref","first-page":"26436","DOI":"10.1074\/jbc.M803692200","article-title":"The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains","volume":"283","author":"Winborn","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib70","doi-asserted-by":"crossref","first-page":"38510","DOI":"10.1038\/srep38510","article-title":"Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in\u00a0vitro assay and an in\u00a0vivo Drosophila synucleinopathy model","volume":"6","author":"Yedlapudi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib71","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1039\/C2OB26648B","article-title":"Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion","volume":"11","author":"Yeoh","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib72","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","article-title":"Iron, brain ageing and neurodegenerative disorders","volume":"5","author":"Zecca","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.019_bib73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(00)00853-3","article-title":"Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice","volume":"281","author":"Zou","year":"2000","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:03:52Z","timestamp":1719212632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817302319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":73,"alternative-id":["S0028390817302319"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.019","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses \u03b1-syn- and MPTP-induced toxicities in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}